Antisense drugs are short, chemically modified, single-stranded nucleic acids (antisense oligonucleotides) that have the ability to target any gene product of interest.
Antisense oligonucleotides offer new opportunities for therapeutic intervention because they act inside the cell to influence protein production. They do this by targeting RNA to either prevent the production of disease-causing proteins, increase the production of proteins deficient in disease, or target toxic RNAs that are unable to generate proteins. Antisense drugs are also able to target emerging biology mediated by microRNAs and long, non-coding RNAs.
AstraZeneca is one of the world’s most exciting bio-pharmaceutical companies. Be inspired by the possibilities of science to make a difference and discover what you can do.
Partner with us
We know that innovation doesn’t happen in isolation, so we partner with others to access the best science and contribute complementary technologies, know-how and molecules.
Learn about us
Our IMED Biotech unit is committed to driving scientific advances in small molecules, oligonucleotides and other emerging technology platforms to push the boundaries of medical science.